Read the rest here: QIAGEN exceeds outlook for Q4 2023, led by 8% CER sales growth in non-COVID products and improved operational profitability
Read the rest here: QIAGEN exceeds outlook for Q4 2023, led by 8% CER sales growth in non-COVID products and improved operational profitability
Original post: BioSyent Declares First Quarter 2024 Dividend
View original post here: atai Life Sciences Appoints Anne Johnson as Chief Financial Officer
See original here: HUTCHMED Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer at ASCO Plenary Series Session
View original post here: VALNEVA: Declaration of shares and voting rights - January 31, 2024
Read more from the original source: 119,021 Orion Corporation A shares converted into B shares
Follow this link: MBX Biosciences Appoints Steven Ryder, M.D., to Board of Directors
Here is the original post: Vaxart Announces Publication in Vaccines of Non-Human Primate Preclinical Data Demonstrating Its Next-Generation Vaccine Candidates Elicit Mucosal and...
View original post here: Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP
See the article here: Ocuphire Pharma Announces Presentation on APX3330 at the Annual Angiogenesis, Exudation, and Degeneration 2024 Conference
Recent Comments